Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
18 Sep, 26
ERS 2026
Key updates on asthma presented at ERS 2026 at Barcelona, Spain from 5th - 9th September, 2026.
18 Sep, 26ERS 2026
Key updates on respiratory infections presented at ERS 2026 at Barcelona, Spain from 5th - 9th September, 2026.
24 Sep, 26Cardiovasc Diabetol.
- Among 6023 adults with CKM stages 0-3, 399 developed CMM in 9 yrs
- Each 1-SD rise in TyG-FI, CTI-FI, CHG-FI, & SHR-FI raised CMM risk by 27-31% (HR 1.27-1.31), while higher eGDR/FI cut risk by 39% (HR 0.61)
- Concurrent insulin resistance & frailty conferred greatest risk, with CHG+FI (HR 6.47) & CTI+FI (HR 6.27)
- An integrated insulin resistance-frailty assessment may improve early CMM stratification (AUC: 0.742)
23 Sep, 26Am J Respir Crit Car...
- Among 99,748 adults with mild-to-moderate asthma after a first exacerbation, 4.1% developed severe asthma within 5 years
- Risk factors included age 40–49 years, exacerbation despite medium-dose ICS, high SABA use, recurrent respiratory infections, and eosinophils ≥0.6×10⁹/L
- High-risk patients with late-onset eosinophilic asthma and recurrent infections had a 30.4% progression risk, supporting early identification.
23 Sep, 26
An 8-year-old boy presented with intermittent fever, bloody stools, and recurrent oral ulcers. Overlapping features of Crohn’s disease and Behçet’s disease posed a diagnostic challenge. Click here to read the diagnosis and treatment.
21 Sep, 26JAMA Ped.
- In 7 real-world studies 7,112 infants, maternal RSVpreF (Respiratory Syncytial Virus bivalent prefusion F protein) vaccination (≥14 days before delivery) reduced RSV-associated LRTI hospitalization by 82% in infants aged 0 to 3 mos
- Vaccine effectiveness against RSV hospitalization remained 78% through 6 mos of age
- Maternal RSVpreF vaccination provided strong protection against severe RSV outcomes to 6 months.
22 Sep, 26
Featured
24 Sep, 26
24 Sep, 26
24 Sep, 26
